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Regulatory T cell (Treg)-mediated immunosuppression is
considered a major obstacle for successful cancer immu-
notherapy. Given their profound effect on the outcome of
immunotherapy trials, Treg frequency and function are
being studied extensively. Unfortunately, no consensus has
been reached about a) the (minimal number of) markers
required to define human Tregs and b) which assay is the
best to measure Treg suppressor function.
We had organized a workshop on the detection and
functional testing of (antigen-specific) Tregs. Based on the
outcome of this workshop and subsequent discussions, we
proposed the following essential marker set for flow cyto-
metric Treg analysis: CD3, CD4, CD25, CD127, FoxP3,
Ki67 and CD45RA. We have validated the use of this
essential marker set in a series of PBMC from healthy
donors and cancer patients, as well as in tumor draining
lymph nodes and freshly isolated tumors. We here show
that the CD3, CD4, CD25, CD127 and FoxP3 markers are
the minimally required markers to define human Treg
cells in peripheral blood, tumors and lymph nodes. Impor-
tantly, as Ki67 and CD45RA provide additional informa-
tion on their activation status, we recommend to also
include these markers in the essential Treg marker set.
Similarly, the discussion on functional assays revealed
that classical suppressor cell assays measuring the inhibi-
tion of responder cell proliferation or cytokine production
in 3-7 day long assays required large numbers of Tregs
and were technically challenging. Other assays, in particu-
lar an assay measuring Treg-mediated prevention of CD69
and CD154 up-regulation on CD4+ T cells was used as
alternative and short (6-20h) assay for assessing human
Treg suppressor function. We studied the ability of Tregs
to inhibit CD25, CD69, CD154 and CD137 up-regulation
on CD4+ and CD8+ T cells and compared this to the
classical assay. Indeed Tregs were able to inhibit aCD3/
CD28-bead-induced up-regulation of CD25, CD69
(on CD4 and CD8) and CD154 (on CD4), but not CD137
(on CD8) on responder T cells. Moreover, we showed that
this excellently correlated with suppression of T cell
proliferation.
In conclusion, we have identified CD3, CD4, CD25,
CD127, FoxP3, Ki67 and CD45RA as the minimally
required marker to define Tregs and showed that the T
cell activation marker assay is a simple, fast and robust
assay to measure Treg suppressive activity. The proposed
essential marker set will be used to launch proficiency
panels and harmonize the phenotypic analysis of Tregs
within the CIMT Immunoguiding Program (CIP) partici-
pating laboratories.
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